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Objective: To conduct the first systematic literature review of clinical trials of N-acetylcysteine (NAC)
for the treatment of substance abuse disorders and addictive behaviors.
Methods: A search of the MEDLINE, Embase and PsycINFO databases was conducted. The
inclusion criteria for the review were clinical trials that used NAC in the treatment of a disorder related
to substance use and/or addictive behaviors, limited to texts in English, Spanish, or French. The
selected studies were evaluated with respect to type of trial, sample size, diagnostic input,
intervention, length of follow-up, outcome variables, and results.
Results: Nine studies analyzing a total of 165 patients met the eligibility criteria and were included in
qualitative analysis. These studies evaluated the role of NAC in cocaine dependence (three studies),
cannabis dependence (two studies), nicotine dependence (two studies), methamphetamine addiction
(one study), and pathological gambling (one study). Five of these trials were double-blind,
randomized, and placebo-controlled.
Conclusions: The studies analyzed suggest a potential role for NAC in the treatment of addiction,
especially of cocaine and cannabis dependence. These results are concordant with the hypothesis of
the involvement of glutamatergic pathways in the pathophysiology of addiction.
Keywords: Drug dependence; addictive behaviors; N-acetylcysteine; glutamatergic receptors;
smoking
Introduction
Substance use disorders and addictive behaviors are
serious public health problems and major contributors to
the global burden of disease.1 Despite recent advances
in technology to study the brain changes related to
addiction, advances in neurobiological knowledge have
not been successfully translated into clinical practice.2,3
Recently, changes in glutamatergic neurotransmission
have been implicated in the pathophysiology of addic-
tion.4 Preclinical studies showed reduced basal glutamate
levels in the nucleus accumbens of rodents chronically
treated with cocaine, and that this reduction appears
to be associated with pleasure-seeking behavior.5-8
Reinstatement of cocaine-seeking behavior was also
related to a reduction in baseline extracellular concentra-
tions of glutamate, resulting in a lower tonic activation of
group 2 metabotropic glutamate receptors (mGluR2/3),
which usually inhibit presynaptic release of glutamate.5 In
the brain, basal levels of extracellular glutamate are
maintained by the exchange of extracellular cystine for
intracellular glutamate.5 Thus, the restoration of basal
levels of glutamate, with a consequent increase in tonic
activation of the mGluR2/3 receptor, has been proposed
as a promising target for pharmacological treatment of
dependence.9
N-acetylcysteine (NAC) is a molecule derived from the
amino acid cysteine and is commonly used in the
treatment of respiratory diseases, in paracetamol poison-
ing, and in the prevention of contrast-induced nephro-
pathy.10,11 Its half-life is approximately 6 hours and 30%
of the drug is excreted by the kidneys.10 Side effects
are mild and infrequent.10 NAC is a precursor of cysteine
and of glutathione, and works as a prodrug of these
molecules.12 Direct administration of cysteine is not
possible in clinical settings because of its limited bio-
availability, toxicity, and insolubility.12
As a prodrug of cysteine, NAC produces interesting
effects in the glutamatergic system. Extracellular cysteine
generated from NAC is transported into the cell, while
intracellular glutamate is transported out of the cell
through the cysteine/glutamate transporter. As noted
above, restoration of extracellular levels of glutamate
increases tonic activation of mGluR2/3 receptors.9,13
These receptors are mostly presynaptic, and inhibit
glutamatergic neurotransmission and excitotoxicity.5
This effect of NAC and its implications for drug addiction
were demonstrated in animal models, in which reestab-
lishing normal levels of extracellular glutamate reduced
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relapse of drug-seeking behavior in rats chronically
treated with cocaine9 and heroin.14
NAC has additional actions on oxidative biology,
by acting as a glutathione precursor and with OH, NO2,
CO3 (-), and thiyl radicals.
15 It has anti-inflammatory
effects, impacts apoptosis and neurogenesis, and
reverses models of mitochondrial toxicity. These pathways
are implicated in the pathways that underlie neuroprogres-
sion in multiple psychiatric disorders; hence, NAC has
been proposed as a neuroprotective agent.16
Taking into consideration these mechanisms of action,
several studies conducted in recent years have tested
NAC for the treatment of addiction. The objective of this
paper was to conduct the first systematic literature review
of clinical trials of NAC for the treatment of disorders
related to substance use and addictive behaviors.
Methods
A search of the electronic medical literature databases
MEDLINE, Embase, and PsycINFO was conducted. The
basic search strategy for MEDLINE was as follows:
(addictive behavior OR addiction OR drug dependence
OR drug abuse OR substance-related disorders OR
substance use disorders OR substance abuse) AND
(N-acetylcysteine OR NAC OR N-acetyl-l-cysteine OR
acetylcysteine OR mercapturic) AND (clinical trials). The
searches conducted in the other databases were analo-
gous. Furthermore, additional studies were obtained
by checking the references of selected articles. The
last search date for inclusion of new references was
May 5, 2013.
The eligibility criteria for the review were clinical trials
that assessed NAC use as the independent variable and
clinical outcomes related to an addiction. Also, the main
inclusion criterion of each trial should be the diagnosis of
a substance use disorder or an addictive behavior. The
search was limited to texts in English, Spanish, or French.
The titles and abstracts of studies identified by the
search strategy were evaluated by two investigators (EA
and ACM) independently and selected items were read in
full. Divergent selection of items was discussed among
the investigators until a consensus was obtained. The
selected studies were evaluated with respect to type of
trial, sample size, diagnostic input, intervention, length of
follow-up, outcome variables, and results.
Results
The MEDLINE, Embase, and PsycINFO search strategy
yielded 117 citations. After removal of duplicate refer-
ences and screening of titles and abstracts, 11 articles
were selected for full-text reading. Using the established
eligibility criteria, nine studies were selected for inclusion
in the review (Figure 1). The studies analyzed included a
total of 165 individuals with substance-use related
disorders or addictive behaviors and 14 controls. The
years of publication were 2007-2012, indicating that
investigation of NAC in this clinical setting is recent.
Table 1 summarizes the main characteristics of the
included studies.
The next section provides a qualitative description of
the analyzed studies, grouped by diagnosis at inclusion.
Cocaine dependence
Three studies evaluated the use of NAC in individuals
with cocaine dependence.17-19 Mardikian et al.17 con-
ducted a 4-week open trial in 23 patients, using 3 different
dosages of NAC, namely, 1.2 g (n=8), 2.4 g (n=9), and
3.6 g (n=6). The sample included 22 males and one
female, and the average age was 40 years. All the
participants sought treatment voluntarily. Of those who
took at least one dose of medication, seven (30%) did not
complete treatment. The variables used to quantify the
effect of intervention on cocaine use were the number of
days of use and the money that was spent on use,
comparing the 28 days prior to treatment with the 28-day
period of treatment. The three intervention groups were
pooled for this analysis, since the sample size did not
allow comparisons between groups. There was a
significant reduction in both the number of days of
cocaine use (mean 8.1 before treatment and 1.1 during,
p = 0.001) and in dollars spent for use ($1,292.8 before
treatment and $52.2 during, p , 0.0001).
LaRowe et al.18 conducted a double-blind, randomized,
placebo-controlled crossover study in 15 hospitalized
individuals (seven men and eight women) who had not
sought treatment voluntarily. The subjects were rando-
mized to placebo or 1.2 g/day of NAC for 3 days. After 4
days, the subjects received the other intervention. The
average age of the sample was 37 years. The primary
outcome was the desire to use, craving, interest in
cocaine reported by the subjects, time spent on slides of
a presentation showing images related to cocaine use,
and electrophysiological measures during the slideshow.
NAC reduced the desire to use cocaine (F = 5.07,
degrees of freedom [df] = 1,13, p , 0.05), interest in
cocaine (F = 5.07, df = 1,13, p , 0.05), and time spent on
the slides in the presence of cues associated with
cocaine use (F = 4.79, df = 1,13, p , 0.05). There were
no differences with respect to craving and electrophysio-
logical variables.
Schmaal et al.19 conducted a magnetic resonance
spectroscopy study to evaluate the effect of NAC on the
levels of glutamate in the dorsal anterior cingulate cortex
(dACC) in patients with cocaine dependence. They
included eight patients with cocaine dependence and 14
healthy controls in an open-label crossover trial, using a
single 2.4-g dose of NAC. Magnetic resonance spectro-
scopy was performed 1 hour after ingestion of the
medication. After administration of NAC, dACC glutamate
levels were reduced in the group of cocaine-dependent
individuals (t(7) = 3.08, p = 0.02). There was no change in
the control group (-0.64, p = 0.53). The Barratt
Impulsiveness Scale (BIS-11) was used to estimate
impulsivity. Higher scores on the BIS-11 were associated
with reduction of glutamate levels in the dACC (b = 0.47,
t(22) = 2.38, p = 0.03).
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Cannabis addiction
Two studies evaluating the use of NAC in cannabis
dependence were found (20, 21). Gray et al.20 conducted
a 4-week open-label study using 2.4 g/day of NAC in 24
patients with cannabis dependence voluntarily seeking
treatment (18 men and six women). The mean age was
19 years. There was a small reduction in self-reported
use of cannabis, from 6.1 days/week of use before
treatment to 5.2 days/week in the second week (p =
0.006), 5.2 days/week in the third week (p = 0.001), and
5.3 days/week in the fourth week (p = 0.03). There was
no significant reduction in the number of joints/day. There
was a reduction in cravings for marijuana, assessed using
the Marijuana Craving Questionnaire (p , 0.01). These
findings notwithstanding, there was no reduction in
urinary levels of cannabinoids during the treatment
period, as measured by semiquantitative cannabinoid
urinary levels corrected for creatinine.
Gray et al.21 conducted a double-blind, randomized trial
using 2.4 g/day of NAC (n=58) or placebo (n=58) for 8
weeks in adolescents with a diagnosis of marijuana
dependence. In addition, individuals in both groups
received a contingency management intervention and
cessation counseling. The sample comprised 116 sub-
jects (84 male and 32 female), with a mean age of
18.9 years. Outcome variables were weekly urinary
dosage of cannabinoids and self-reported cannabis use.
Participants in the NAC group had more than twice the
odds of having a negative urine cannabinoid test
compared to the placebo group (odds ratio = 2.4,
95%CI 1.1-5.2; c2 = 4.72, p = 0.029). There was no
between-group difference in the number of reported days
of marijuana use.
Nicotine addiction
Three studies evaluated the use of NAC in patients with
nicotine dependence.22,23 Knackstedt et al.22 conducted
a double-blind, randomized trial in a sample of 33
subjects (mean age 50 years; 19 male and 14 female).
Of the 33 subjects randomized, four did not complete the
study. Of the 29 subjects who completed the study, 14
were treated with 2.4 g of NAC and 15 received placebo
for 4 weeks. The efficacy endpoints were: 1) scores of
craving measured by the Questionnaire for Smoking
Figure 1 Systematic review flowchart
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Urges - Brief (QSU-B), 2) symptom scores of nicotine
withdrawal measured by the Minnesota Withdrawal Scale
(MNWS), 3) measurement of expired CO2, and 4) self-
reported cigarette use. There was no significant differ-
ence between groups in the number of cigarettes smoked
daily (17.7 in NAC group vs. 19.7 in the placebo group).
On exploratory analysis, there was a trend toward a time
effect in cigarettes smoked weekly (p = 0.06) and a
significant effect for day on analysis of cigarettes smoked
daily (F(26,600) = 2.4, p , 0.001), although alcohol
consumption was a significant covariate in this interac-
tion. There was no significant difference in measured CO2
levels or in QSU-B or MNWS scores.
Schmaal et al.23 conducted a double-blind, rando-
mized, placebo-controlled study to evaluate the effect of
NAC on short-term abstinence from cigarettes. Twenty-
three individuals who smoked at least 15 cigarettes/day
were initially randomized. Of the 22 patients who
completed the study, 10 received 3.6 g of NAC and 12
received placebo for 3.5 days. The mean age of the
sample was 20.7 years (nine men and 13 women).
Patients were asked to cease smoking, and abstinence
was determined by measurement of expired CO2.
Severity of withdrawal symptoms and craving were
assessed using the MNWS and QSU-B respectively. On
the last day of treatment, participants were asked to
smoke one cigarette and rate, on a visual scale of 1 to
100, the pleasure obtained from that cigarette. There
was no significant between-group difference in MNWS
or QSU-B scores. The group that received NAC
reported significantly less pleasure in the first cigarette
smoked compared to the placebo group (42.6 vs. 65.6,
p = 0.04).
Methamphetamine addiction
Only one study has evaluated the use of NAC in
individuals with methamphetamine dependence.24 In an
8-week double-blind trial, 39 patients were randomized,
and 31 returned for at least one follow-up evaluation.
They received either placebo (n=17) or a combination of
naltrexone and NAC (n=14). Doses ranged from 0.6 g
NAC and 50 mg naltrexone in the first 2 weeks up to 2.4 g
NAC and 200 mg naltrexone in the last 2 weeks. The
average age of the sample was 36.8 years (22 men and
nine women). The primary outcome was craving severity
assessed by the Penn Craving Scale. Secondary out-
comes were the number of days of methamphetamine
use and urine toxicology. The authors reported a trend
toward reduction in the number of days/week of use in the
intervention group compared with the placebo group (6.7
vs. 4 days, p = 0.081). Nonetheless, there were no
statistically significant between-group differences in any
of the outcome variables.
Table 1 Clinical trials of NAC in addictive behavior
Disorder/study Design n Intervention Results
Cocaine dependence
Mardikian1 4-week open-label trial 23 NAC 1.2 g (n=8); 2.4 g
(n=9); 3.6 g (n=6)
Reduction in self-reported cocaine use
LaRowe2 Double-blind randomized
crossover trial
15 NAC 1.2 g or placebo
for 3 days, followed by a
3-day crossover phase
after 4 days
Less self-reported desire to use and less
response to cocaine cues during the NAC phase
Schmaal3 Open-label randomized
crossover trial
22 Single 2.4 g NAC dose
phase and a placebo
phase in patients (n=8)
and controls (n=14)
Reduction in glutamate levels in the dACC of
cocaine-dependent subjects after NAC
Cannabis dependence
Gray4 4-week open-label trial 24 NAC 1.2 g Reduction in self-reported craving
Gray5 8-week double-blind
randomized trial
116 NAC 2.4 g (n=58) or
placebo (n=58)
More negative urine tests in the NAC group




29 NAC 2.4 g (n=14) or
placebo (n=15)
NAC group reported a non-significant reduction
in the number of cigarettes smoked
Schmaal7 3.5-day double-blind
randomized trial
22 NAC 3.6 g (n=10) or
placebo (n=12)









No differences in primary and secondary
outcomes
Pathological gambling
Grant9 I) 8-week open-label and
II) 6-week double-blind
trial in responders
13 NAC 1.8 g (n=6)
placebo (n=7)
I) Reduction in baseline symptoms (20.3 vs.
11.8, p , 0.001); II) More responders in
NAC group (83.3 vs. 28.6)
95%CI = 95% confidence interval; dACC = dorsal anterior cingulate cortex; NAC = N-acetylcysteine.
NAC in the treatment of addictions 171
Rev Bras Psiquiatr. 2014;36(2)
Pathological gambling
Grant et al.25 conducted a clinical trial to assess the effect
of NAC in subjects with pathological gambling. The study
had two phases: an initial 8-week open-label phase with
increasing doses of NAC (0.6 to 1.8 g) and a double-blind
discontinuation of medication in responders, lasting 6
weeks. The primary outcome variable was the severity of
symptoms of pathological gambling measured by the
Yale Brown Obsessive Compulsive Scale Modified for
Pathological Gambling (PG-YBOCS). Response was
defined as a reduction of 30% or more in PG-YBOCS
scores. The authors also used the Gambling Symptom
Assessment Scale (G-SAS), a self-report scale of
symptom severity. Twenty-nine patients (15 men and 12
women) were included in the open study. Two patients
did not return for any of the assessments and were
excluded from the analysis. The average age was 50.8
years. There was a 41.9% reduction in PG-YBOCS
scores during the open-label phase, from 20.3 to 11.8
(t(50) = 4.7, p , 0.001). There was also a 40.2%
reduction in the G-SAS, from 32.3 to 19.3 (p , 0.001).
There were 16 responders, and 13 agreed to continue in
the double-blind discontinuation phase. During this
phase, six patients were randomized to continue using
NAC and seven to receive placebo. Of those allocated to
receive NAC, 83.3% still fulfilled response criteria at the
end of 6 weeks vs. 28.6% in the discontinuation group
(Fisher’s exact test = 0.078, Q coefficient = -0.55). There
was a trend toward a difference between the groups with
respect to changes in PG-YBOCS and G-SAS scores,
but it was not statistically significant (p = 0.095 for the
PG-YBOCS and p = 0.06 for G-SAS).
Discussion
We conducted a systematic literature review of clinical
trials of NAC for the treatment of individuals with
disorders related to substance use or addictive behaviors.
Nine studies, representing a total of 243 patients, met the
eligibility criteria and were included in the qualitative
analysis. These studies evaluated the efficacy of NAC in
cocaine dependence,17-19 cannabis dependence,20,21 nico-
tine dependence,22,23 methamphetamine dependence,24
and pathological gambling.25 Five of these trials were
double-blind, randomized, and placebo-controlled.18,21-24
Among them, we highlight the study by Gray et al.,21 with
the largest sample size (n=116), which evaluated the use of
NAC in adolescents with marijuana dependence. This
study found a significant reduction in the number of
negative urine tests in the NAC group. Overall, despite
methodological limitations, the compiled studies indicate
a potentially important role for NAC in the treatment of
cocaine dependence and marijuana dependence. The
findings in the treatment of pathological gambling were
limited to secondary outcomes. Studies of NAC in
methamphetamine addiction and smoking presented
negative results.
Two relevant studies screened to be read in full did not
meet the eligibility criteria and were excluded from the
qualitative analysis. In a subgroup of cocaine-dependent
individuals that was included in another study,18 LaRowe
et al.26 presented preliminary results regarding safety,
tolerability, self-reported craving, and withdrawal symp-
toms. Thirteen patients received placebo or 600 mg NAC
twice daily during a 3-day hospitalization. Individuals
received the other intervention during another 3-day
hospitalization in the following week. No unexpected side
effects were reported, and none of the serious side
effects associated with intravenous NAC, such as allergic
reactions or seizures, occurred. Only mild side effects
were reported, without differences between conditions.
There were no between-group differences in self-reported
craving and withdrawal symptoms, although within-group
analysis of these variables revealed a significant differ-
ence between pre- and post-treatment only in the NAC
condition.
The other excluded study assessed reduction in
substance use among individuals with bipolar disorder.27
Data on substance use were collected from a 24-week,
double-blind, randomized, placebo-controlled trial of NAC
for depressive symptoms in bipolar disorder.28 Individuals
received 2 g/day NAC (n=38) or placebo (n=37). The
frequency of substance use in the sample was as follows:
78.7% drank alcohol, 45.3% smoked tobacco, and 92%
consumed caffeine. Fewer than six participants used
other substances, precluding a comparison between
groups. There were no between-group differences in
alcohol and tobacco use. Caffeine use was significantly
lower for NAC-treated participants compared with pla-
cebo at week 2 of treatment, but not at other study visits.
Despite negative findings for their main outcome
variables, the studies of NAC in nicotine and metham-
phetamine addiction provided interesting results. In
a 4-week, double-blind, randomized controlled trial,
Knackstedt et al.22 reported a non-significant reduction
in self-reported daily cigarettes smoked in the NAC group
as compared with placebo (17.7 vs. 19.7). However, the
exploratory analysis showed a significant effect on daily
cigarettes smoked in the NAC treatment group (F(26,600)
= 2.4, p , 0.001). In another double-blind randomized
trial of NAC in nicotine dependence, Schmaal et al.23
assessed craving and withdrawal symptoms in short-term
(3.5 days) abstinence, with negative results. Interestingly,
individuals in the NAC group reported significantly less
pleasure in the first cigarette smoked after the abstinence
period, compared to the placebo group (42.6 vs. 65.6, p =
0.04). Finally, Grant et al.24 conducted an 8-week double-
blind randomized controlled trial of NAC plus naltrexone
for the treatment of metamphetamine addiction. The
results were negative for craving and drug use. One point
to be considered in this study is the dose of NAC used.
The intervention group only received 2.4 g of NAC in the
last 2 weeks of the trial, ranging from 0.6 to 1.8 g in the
previous 6 weeks. The effective dose of NAC in most
trials was at least 2.4 g. The low dose of NAC used during
most of the trial could have contributed to the negative
results.
These findings provide limited support for the hypothe-
sized neurobiological action of NAC in the treatment of
E Asevedo et al.172
Rev Bras Psiquiatr. 2014;36(2)
addiction: namely, restoring extracellular glutamate con-
centrations.9 There is evidence from animal studies
demonstrating that a reduction in the concentration of
extracellular glutamate in the nucleus accumbens is
associated with drug-seeking behavior and relapse.5-8
Another important finding in animal models is the
reduction in firing rates of glutamatergic projections from
regions of the prefrontal cortex, such as the anterior
cingulate cortex, to the nucleus accumbens.29
One study included in this review sought to assess
whether the glutamatergic changes found in animal
models of dependence occur in humans and determine
whether NAC could interfere with these changes.19 The
primary outcome measure used was glutamate levels
measured by nuclear magnetic resonance spectroscopy
in the dACC of patients with cocaine dependence. Eight
patients with cocaine dependence and 14 controls were
enrolled in an open-label crossover trial, using a single
dose of 2.4 g NAC. Resonance spectroscopy imaging
was performed 1 hour after ingestion of the medication. In
the pretreatment group, patients had lower levels of
glutamate in the dACC compared to the control group (p =
0.04). Interestingly, after administration of a single dose
of NAC, there was restoration of glutamate levels in
patients, which became similar to those in the control
group.
Although less highlighted in the literature, another
possible mechanism of action of NAC in addiction
involves its antioxidant properties. Cysteine provided
by NAC increases cellular production of glutathione.30
Glutathione is a tripeptide formed by the linkage of
cysteine, glycine, and glutamate, and is the most
prevalent intracellular antioxidant.31 Intracellular avail-
ability of cysteine is the rate-limiting step in the biosynth-
esis of glutathione.30 The molecule exists in the reduced
form (GSH) and in the oxidized dimeric form (GSSG).31
The reduced form serves as an electron donor, prevent-
ing cellular damage from reactive oxygen species.30
Chemical reactions related to the biosynthesis and
metabolism of glutathione form the gamma-glutamyl
cycle, which is also involved in the formation of DNA
precursors.31 The redox modulation produced by NAC
may have an important protective effect on the brain,
possibly reducing neuroprogression32,33 associated with
psychiatric diseases and with chronic use of potentially
neurotoxic drugs.34,35 This rationale is especially relevant
in individuals at early stages of disease, when less
structural brain damage is expected.33
The safety profile of NAC and its favorable tolerability
highlight its potential for clinical use.10 Being an over-the-
counter medication, it could be useful in patients hesitant
to accept conventional psychotropic medications. In
addition, there is an understandable concern by clinicians
regarding prescription of psychotropic medications in
adolescents, a target population in the treatment of
addiction. Firstly, in this group of patients, there is a
potential for paradoxical reactions, such as increased
risk of suicidal behavior with the use of antidepressants36
and risk of agitation using benzodiazepines.37 Another
important issue is the adverse effect profile of these
medications in chronic use. Some agents may induce
weight gain, hypercholesterolemia, hypertriglyceride-
mia, and increased peripheral insulin resistance.38 As a
consequence, there may be an increased risk of
diabetes and cardiovascular disorders.39 Finally, the
effects of long-term use of these medications on the
developing brain are unknown.40 These concerns are
even more justifiable in the context of addiction, in
which few medications are formally approved for use
and the effect size is small.41 Two studies included in
this review addressed adolescents, both in the treat-
ment of cannabis dependence, suggesting positive
results regarding self-reported craving and negative
urine tests.20,21
The findings reported in this systematic review should
be examined in light of the substantive limitations of many
of the studies. The heterogeneity of the studies, with
different diagnoses, designs, interventions, follow-up
periods, and outcomes, precluded a pooled quantitative
analysis of data. The studies were qualitatively described,
thus limiting generalization of the findings of the review.
More specifically, the analyzed studies included patients
with cocaine dependence, marijuana dependence,
nicotine dependence, methamphetamine dependence,
and pathological gambling. As for design, there were
open-label studies, double-blind crossover, double-blind
placebo-controlled, and double-blind discontinuation de-
signs. It goes without saying that only large-scale,
randomized, double-blind, placebo-controlled studies
can be used as level-one evidence; the rest are
hypothesis-generating only. Regarding interventions, the
studies used different doses of NAC, ranging from 0.6 to
3.6 g daily, which may have influenced the results. Low
doses of NAC may have been insufficient to produce the
desired increase in extracellular glutamate. On the other
hand, high doses may also have been detrimental,
leading to excessive levels of extracellular glutamate
and indiscriminate stimulation of other glutamate recep-
tors rather than the intended stimulation of mGluR2/3.
The optimal dose of NAC for the treatment of addictions is
still undetermined. Nevertheless, the finding that 2.4 g of
NAC restored glutamate levels in the dACC of cocaine-
dependent patients may provide a temporary reference.19
With respect to follow-up time, a few studies have
evaluated the effect of NAC in the very short term,
ranging from 1 hour after administration to 3.5-day follow-
up. Others assessed a longer follow-up period, of 4 to 8
weeks. Nevertheless, considering that addiction is a
chronic disease, longer follow-up periods are needed to
adequately determine the effect of a medication. Another
important limitation of this review is the sample size of the
included studies; only one study had a sample of more
than 100 individuals.
To the best of our knowledge, this is the first systematic
review of the literature evaluating the use of NAC in the
treatment of addiction. The studies analyzed suggest a
potential role for NAC in this setting, especially in cocaine
and cannabis dependence. These results are concordant
with the hypothesis of the involvement of glutamatergic
pathways in the pathophysiology of addiction.
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